Date: 2017-04-03
Type of
information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the American Association for Cancer Research (AACR) Annual Meeting
Company: Five Prime Therapeutics (USA - CA)
Product: FPA008 (cabiralizumab)
Action
mechanism:
- monoclonal antibody. FPA008 is an antibody that inhibits colony stimulating factor-1 receptor (CSF1R). It blocks the activation and survival of monocytes and macrophages. Inhibition of CSF1R in inflamed RA joints blocks the production of inflammatory cytokines by macrophages and inhibits osteoclasts, monocyte-lineage cells that can cause bone erosions and joint destruction. Inhibition of CSF1R in many cancers reduces the number of immunosuppressive tumor-associated macrophages (TAMs), thereby facilitating an immune response against tumors.
Disease:
Therapeutic
area: Cancer - Oncology
Country:
Trial
details:
Latest
news:
- • On April 3, 2017, Five Prime Therapeutics announced that a poster featuring preclinical data related to Five Prime's CSF-1R antibody, cabiralizumab (FPA008), was presented at the 2017 American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C. The poster is titled "Antibody-Based Inhibition of CSF-1R as a Component of Combination Immunotherapy in Preclinical Models".
The colony stimulating factor 1 receptor (CSF-1R) signaling pathway promotes tumor progression via the recruitment, differentiation, and survival of immuno-suppressive, M2 polarized, tumor-associated macrophages (TAMs). Five Prime has developed cabiralizumab (FPA008), an IgG4 antibody against CSF-1R that blocks the ability of both CSF-1 and IL-34 to bind and activate this receptor, thereby modulating the immune response to tumorigenesis.
Five Prime has identified alterations in the tumor microenvironment that occur upon CSF-1R inhibition, including significant reduction of immunosuppressive M2 TAMs and an increase in tumor PD-L1 expression. Notably, when dosing in combination, the blockade of CSF-1R and PD-1/PD-L1 results in a significant increase in CD8+ T cells within the tumor. The results show that, when added to PD-1/PD-L1 blockade, the surrogate antibody for FPA008 can significantly enhance anti-tumor efficacy.
Is
general: Yes
